Select country set
Menu Shopping cart 0,00 Search
Manufactured by BioVendor


  • Regulatory status:RUO
  • Source:E. coli
Please select your region to see available products and prices.
Cat. No. Size Price

RP1792870500 500 IU
RP1792872500 2500 IU
RP17928710000 10,000 IU
PubMed Product Details
Technical Data


L-Asparaginase was purified from E. coli ASI.357


E. coli


Greater than 96.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.


The enzyme was lyophilized with no additives.


It is recommended to reconstitute the lyophilized L-Asparaginase in 18MOhm water at 1 mg/ml.


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Two years when stored at –20°C, 2 weeks at 4°C.

Physical Appearance

Sterile filtered white lyophilized (freeze-dried) powder.


BioVendor's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.



L-Asparaginase is an enzyme that depletes L-Asparagine “an important nutrient for cancer cells” resulting in cancer/tumor cell starvation. L-asparaginase is an anti-tumor agent derived from E.coli.,which can inhibit the growth of malignant cells. It is used mainly for the induction of remission in acute lymphoblastic leukaemia. Because of the lymph node origin of malignant B cells in Multiple Myeloma, L-Asparagine is an essential amino acid for their cell metabolism, and, consequently, L-Asparaginase may be of value in managing the disease. The rationale behind asparaginase is that it takes advantage of the fact that ALL cellsare unable to synthesize the non-essential amino acidasparagine whereas normal cells are able to make their own asparagine. These leukemic cells depend on circulating asparagine. Asparaginase however catalyzes the conversion of L-asparagine to aspartic acid and ammonia. This deprives the leukemic cell of circulating asparagine.

Product References (5)


  • Fernandez CA, Cai X, Elozory A, Liu C, Panetta JC, Jeha S, Molinelli AR,Relling MV. High-throughput asparaginase activity assay in serum of children withleukemia. Int J Clin Exp Med. 2013 Aug 1;6(7):478-87. Print 2013. PubMed PMID:23936585; PubMed Central PMCID: PMC3731178. See more on PubMed
  • Fernandez CA, Smith C, Karol SE, Ramsey LB, Liu C, Pui CH, Jeha S, Evans WE,Finkelman FD, Relling MV. Effect of premedications in a murine model ofasparaginase hypersensitivity. J Pharmacol Exp Ther. 2015 Mar;352(3):541-51. doi:10.1124/jpet.114.220780. Epub 2015 Jan 8. PubMed PMID: 25573198; PubMed CentralPMCID: PMC4352598. See more on PubMed
  • Liu Y, Smith CA, Panetta JC, Yang W, Thompson LE, Counts JP, Molinelli AR, PeiD, Kornegay NM, Crews KR, Swanson H, Cheng C, Karol SE, Evans WE, Inaba H, PuiCH, Jeha S, Relling MV. Antibodies Predict Pegaspargase Allergic Reactions andFailure of Rechallenge. J Clin Oncol. 2019 Aug 10;37(23):2051-2061. doi:10.1200/JCO.18.02439. Epub 2019 Jun 12. PubMed PMID: 31188727; PubMed CentralPMCID: PMC6804844. See more on PubMed
  • Sullivan LB, Luengo A, Danai LV, Bush LN, Diehl FF, Hosios AM, Lau AN,Elmiligy S, Malstrom S, Lewis CA, Vander Heiden MG. Aspartate is an endogenousmetabolic limitation for tumour growth. Nat Cell Biol. 2018 Jul;20(7):782-788.doi: 10.1038/s41556-018-0125-0. Epub 2018 Jun 25. PubMed PMID: 29941931; PubMedCentral PMCID: PMC6051729. See more on PubMed
  • Tiziani S, Kang Y, Choi JS, Roberts W, Paternostro G. Metabolomic high-contentnuclear magnetic resonance-based drug screening of a kinase inhibitor library.Nat Commun. 2011 Nov 22;2:545. doi: 10.1038/ncomms1562. PubMed PMID: 22109519;PubMed Central PMCID: PMC5529142. See more on PubMed
Related Products Docs